Conversely, the use of a PAD inhibitor in the PAD/LPS model reversed these findings, suggesting that inhibition of PAD could potentially provide a therapeutic option to reduce the breakdown of elastin and limit the formation of EDPs [43]. The gene discussed is ELN; the disease is peripheral arterial disease.